Blog
RSS FeedPosted by Michael Wonder on 13 Feb 2017
The challenges of generating evidence to support precision medicine
13 February 2017 - Major recent advances in science and technology now enable new kinds of measurements that can characterise an ...
Posted by Michael Wonder on 08 Feb 2017
AusBiotech to initiate clinical trials advisory group
7 February 2017 - AusBiotech is inviting members to express interest in joining a new advisory group to provide guidance ...
Posted by Michael Wonder on 01 Feb 2017
Clinical data for two more medicines now available online
1 February 2017 - First publication of clinical data corresponding to a withdrawn application. ...
Posted by Michael Wonder on 19 Jan 2017
Six month market exclusivity extensions to promote research offer substantial returns for many drug makers
18 January 2017 - To incentivise pharmaceutical manufacturers to invest in areas of unmet medical need, policy makers frequently propose extending ...
Posted by Michael Wonder on 18 Jan 2017
Pharmaceutical industry financial ties linked to 'positive' outcomes in clinical trials for new drugs
18 January 2017 - A new study has found links between medical researchers' financial ties with pharmaceutical companies and "positive" ...
Posted by Michael Wonder on 17 Jan 2017
Composite endpoints and the distortion of risk–benefit analysis
17 January 2017 - Evidence-based medicine is a reassuring phrase, but when we prescribe has the evidence for safety and efficacy ...
Posted by Michael Wonder on 11 Jan 2017
National Cancer Institute and drug companies aim to speed up clinical trials
11 January 2017 - The National Cancer Institute launched an effort Wednesday to speed up clinical trials by getting researchers ...
Posted by Michael Wonder on 04 Jan 2017
The changing face of clinical trials: the large pharmaceutical company perspective
4 January 2017 - Large pharmaceutical companies conduct clinical trials to evaluate efficacy and identify safety issues for candidate drugs as ...
Posted by Michael Wonder on 27 Dec 2016
Negative control outcomes: a tool to detect bias in randomised trials
27 December 2016 - Investigators have several design, measurement, and analytic tools to detect and reduce bias in epidemiological studies. One ...
Posted by Michael Wonder on 15 Dec 2016
Transforming evidence generation to support health and health care decisions
14 December 2016 - Making better choices about health and health care requires the best possible evidence. Unfortunately, many of the ...
Posted by Michael Wonder on 13 Dec 2016
EMA hosts workshop on adaptive pathways
13 December 2016 - Broad range of stakeholder questions addressed. ...
Posted by Michael Wonder on 08 Dec 2016
Interpreting geographic variations in results of randomised, controlled trials
7 December 2016 - Clinical triallists generally accept the premise that surprising results in subgroups of a randomised, controlled trial most ...
Posted by Michael Wonder on 06 Dec 2016
Failure of investigational drugs in late-stage clinical development and publication of trial results
5 December 2016 - Many investigational drugs fail in late-stage clinical development. A better understanding of why investigational drugs fail can ...
Posted by Michael Wonder on 05 Dec 2016
World-first clinical trial of cannabis for chemotherapy patients kicks off in NSW
5 December 2016 - Lauren Hew knows she'll be fighting cancer until it wins. ...
Posted by Michael Wonder on 30 Nov 2016
Drug approval by regulators: who watches the watchers?
30 November 2016 - In the latest issue of The Lancet Oncology, Ian Tannock and colleagues discuss some important parameters governing ...